GlassScriptPhysician profile
Diane L Mitchell
NPI 1124035399
$8,550.55
in general payments reported to CMS, 2019-2025
30 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,517 · 2022: $1,580 · 2023: $1,934 · 2024: $1,959 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,440 · Education: $13.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,440.32 |
| Education | $13.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,580.04 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,603.86 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $624.79 | 2021-2025 | Stelara, Tremfya, Remicade |
| Ardelyx, INC. | $537.77 | 2022-2025 | Ibsrela |
| Novo Nordisk INC | $326.26 | 2021-2023 | Wegovy |
| Gilead Sciences, INC. | $297.51 | 2021-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $296.67 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $223.70 | 2021-2024 | Linzess |
| Genzyme Corporation | $203.27 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $192.07 | 2021-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $172.96 | 2022-2025 | Dupixent |
| Evoke Pharma, INC. | $154.98 | 2021-2023 | Gimoti |
| Takeda Pharmaceuticals U.S.A., INC. | $153.95 | 2021-2024 | Gattex, Entyvio |
| Nestle Healthcare Nutrition INC. | $150.79 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $122.39 | 2021-2024 | Dificid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $121.19 | 2021-2024 | |
| Qol Medical, LLC | $115.96 | 2022-2024 | Sucraid, Sucraid |
| Celgene Corporation | $115.92 | 2022-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $98.02 | 2023-2025 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $79.91 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $65.16 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $54.13 | 2021-2022 | |
| Organon LLC | $53.47 | 2022-2023 | Renflexis, Hadlima |
| Daiichi Sankyo INC. | $53.28 | 2022-2023 | Injectafer |
| Medtronic, INC. | $48.23 | 2024 | Interstim |
| Braintree Laboratories, INC. | $28.18 | 2023 | Sutab |
| Celltrion USA INC. | $27.92 | 2024-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $20.20 | 2023 | |
| Boston Scientific Corporation | $14.78 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.